Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization/ER 19% Improvement Relative Risk Hospitalization/ER (b) 12% Hospitalization/ER (c) 12% Hospitalization/ER (d) 10% c19fluvoxamine.com Fritz et al. Fluvoxamine for COVID-19 Prophylaxis Favors fluvoxamine Favors control
Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2
Fritz et al., Translational Psychiatry, doi:10.1038/s41398-022-02109-3
22 Aug 2022    Source   PDF   Share   Tweet
Retrospective 25,034 COVID+ outpatients showing significantly lower ER/hospitalization with antidepressants and FIASMA antidepressants, and a dose-dependent response.
risk of hospitalization/ER, 19.4% lower, RR 0.81, p = 0.69, treatment 4 of 17 (23.5%), control 1,896 of 20,457 (9.3%), adjusted per study, odds ratio converted to relative risk, fluvoxamine, multivariable.
risk of hospitalization/ER, 11.9% lower, RR 0.88, p = 0.03, treatment 707 of 3,414 (20.7%), control 1,896 of 20,457 (9.3%), adjusted per study, odds ratio converted to relative risk, FIASMA, multivariable.
risk of hospitalization/ER, 11.9% lower, RR 0.88, p = 0.04, treatment 559 of 2,744 (20.4%), control 1,896 of 20,457 (9.3%), adjusted per study, odds ratio converted to relative risk, SSRI, multivariable.
risk of hospitalization/ER, 10.1% lower, RR 0.90, p = 0.04, treatment 971 of 4,577 (21.2%), control 1,896 of 20,457 (9.3%), adjusted per study, odds ratio converted to relative risk, all antidepressants, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fritz et al., 22 Aug 2022, retrospective, USA, peer-reviewed, 5 authors, study period 1 March, 2020 - 16 May, 2021.
Contact: bafritz@wustl.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit